Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Montserrat Rodriguez-Reyes"'
Publikováno v:
BMC Primary Care, Vol 23, Iss 1, Pp 1-9 (2022)
Abstract Background Chronic kidney disease (CKD) is a highly prevalent disease worldwide. A basic pillar for the management of a patient with CKD is the safe use of drugs. Inadequate dosing of medication or contraindicated drugs in renal impairment c
Externí odkaz:
https://doaj.org/article/bfbb311965c7427795bae762342b7592
Autor:
José Miguel Sotoca-Momblona, Montserrat Rodriguez-Reyes, Neus Pagès-Puigdemont, Concepció Bartres-Viñas, Sergio Rodriguez-Tajes, Sabela Lens-García, Zoe Mariño-Mendez
Publikováno v:
Ars Pharmaceutica, Vol 61, Iss 1, Pp 45-47 (2020)
RESUMEN Objetivos: Determinar la efectividad del tratamiento de la hepatitis C crónica definida como la respuesta viral sostenida a las 12 semanas (RVS12) tras la finalización del tratamiento con fármacos antivirales de acción directa (AAD) (glec
Externí odkaz:
https://doaj.org/article/681c38ef8530431787c41ed01fa0dca2
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 46:767-771
What is known and objective Dose banding is a strategy to optimize processing without reducing patient safety. Prescribed doses are rounded up or down to predetermined standard doses. Although it has been mostly used in chemotherapy, other drugs are
Autor:
Montserrat Rodriguez-Reyes, Dolors Soy-Muner, Laura Guerrero-Molina, Carmen López-Cabezas, Judit Roura-Turet
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 78(15)
Purpose To evaluate the stability of 5% vancomycin ophthalmic solution prepared using balanced salt solution (BSS) and stored at –20°C in polypropylene containers. Methods Six batches of vancomycin 50 mg/mL eyedrops were aseptically prepared. One
Autor:
Montserrat Rodriguez-Reyes, JM Sotoca
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance It is well documented that direct acting antiviral (DAA) combinations in the treatment of hepatitis C virus (HCV) achieve high rates of sustained virologic response. However, studies on retreatment options for patients who h
Publikováno v:
Medicina Clínica (English Edition). 157:85-86
Publikováno v:
Medicina Clínica. 157:85-86
Autor:
E López-Suñé, C Codina-Jané, E Calvo-Cidoncha, M Tuset-Creus, Montserrat Rodriguez-Reyes, A Soriano-Viladomiu
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Ceftolozane/tazobactam is a novel antibiotic commonly used in infections by gram-negative bacteria resistant to conventional antibiotics. Drug-dosing errors are common in patients with renal impairment and can cause adverse effects or poor
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Glecaprevir/pibrentasvir (G/P) is a pangenotypic, once-daily, ribavirin-free direct-acting antiviral treatment for hepatitis C virus (HCV) infection in patients with and without compensated cirrhosis. Purpose Our aim was to assess the effe
Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients
Autor:
G. Gutierrez-Garcia, N. Borràs-Maixenchs, M. Cervera-Carbonell, E. Carcelero-San Martín, M. Valverde-Bosch, Montserrat Rodriguez-Reyes, G. Riu-Viladoms, M. Bosch-Damas
Publikováno v:
Annals of Oncology. 30:v839
Background The oral, fixed-combination NEPA containing netupitant and palonosetron target crucial pathways involved in both acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients with highly emetogenic chemotherapy.Hematopoieti